A thorough process to assess and validate future development and acquisition targets, optimising portfolio and disease area strategy and aligning key stakeholders to plan.
Life sciences leaders face growing market complexity, making it increasingly difficult to translate strategy into real-world impact
Changing Health Landscape
- Innovative therapies and technologies are fundamentally disrupting care pathways
- Healthcare systems are constrained in clinician and management capacity, as well as in financial and technical resources
- Patient, HCP and payer expectations and behaviors are changing dramatically
Organizational Challenges
- Complexity in patient pathways and cross-stakeholder dynamics are not sufficiently understood
- Important decisions are still made from an internal rather than a truly customer-centric perspective
- Functional teams operate with different views of the market based on their silos and place in the value chain
The Result
- Lower uptake as adoption lags because strategies miss the real decision points
- Misaligned investment with resources focused in the wrong places, limiting ultimate impact
- Lost value as asset potential is eroded across the lifecycle, and ”beyond molecule” competition bites
Ready to discuss how we can help?
Ready to discuss how we can help?
Our three deep specialisms cohere to help our clients solve these real world challenges and achieve their market ambitions
While we work across the life sciences value chain, we focus on three areas where clients tell us our insight and expertise create the greatest impact; by combining these capabilities, we differentiate from other consulting firms.
Researching, designing and improving real-world customer experience across patients, HCPs and other key stakeholders, through solutions which drive behavior change to unlock value and differentiation at global and local market level.
Maximising and accelerating asset and portfolio performance, from early strategy through launch and lifecycle optimisation, addressing key market and stakeholder needs to drive medicines utilisation and differentiation.
Transforming key business functions to maximize effectiveness and efficiency at scale, through modernized operating models, roles, structures, KPIs, AI and digital enablement, embedded via enterprise-level behavior change.
From Step Zero-360 to measurable impact: we unlock value across assets, markets, and execution in the changing healthcare landscape
LSC Step Zero-360
LSC Step Zero-360
LSC Step Zero-360 creates a new foundation to develop strategy
- Single, holistic, outside-in view of patient pathways, HCP decisions and system dynamics
- A shared source of truth across clinical, medical, access, commercial and other teams
- Identification of the critical moments and decisions that truly drive outcomes
Asset Value
Asset Value
- Sharper, more confident decisions across your portfolio
- Differentiated strategies from development through launch
- Focus on the highest-value opportunities
Asset and portfolio value maximised at every stage.
Market Activation
Market Activation
- Go-to-market grounded in real-world dynamics, not internal structures
- The right stakeholders engaged at the moments that matter
- Faster adoption and stronger in-market performance
Improved adoption, advocacy and in-market performance.
Execution & Change
Execution & Change
- Aligned organisation, capabilities, and ways of working
- Strategy driven into embedded execution and behaviour change
- Measurable, lasting outcomes
Strategy translated into consistent execution and sustained, measurable impact.
Explore our capabilities
Explore how our core capabilities, enabled by AI and advanced analytics, work together to drive belief, accelerate adoption, and create the momentum your brand needs to lead.
Explore our Strategy Consulting case studies
Explore our Strategy Consulting case studies
Pipeline prioritisation, positioning and planning
Pipeline prioritisation, positioning and planning
A robust, cross-functional approach to set the strategic direction for pipeline assets and their target indications in the context of an existing portfolio.
See case study
Global evidence generation strategy
Global evidence generation strategy
Development of an evidence-generation strategy and expanded LCM opportunities to drive competitive differentiation aligned to stakeholder market-value drivers.
See case study
Accelerating the pathway to launch for a breakthrough oncology asset
Accelerating the pathway to launch for a breakthrough oncology asset
Our client needed a partner to help them navigate the journey to launch and successfully bring their product to market while creating a model for future launches across the organisation.
See case study
Digitising Medical planning
Digitising Medical planning
Digitising of Global oncology Medical strategy plans across assets.
See case study
Outsourcing strategy for scalable growth
Outsourcing strategy for scalable growth
Target Clinical Development outsourcing operating model.
See case study
Explore our Strategy Consulting white papers
Explore our Strategy Consulting white papers
From GLP-1 Breakthrough to Healthcare System Readiness
From GLP-1 Breakthrough to Healthcare System Readiness
The first wave of glucagon-like peptide-1 (GLP-1) therapies applied beyond diabetes settled one question decisively: pharmacological intervention in obesity works. But the challenge has moved on.
See article and view paper
Bridging the gap from scientific progress to system readiness in Alzheimer’s disease (AD)
Bridging the gap from scientific progress to system readiness in Alzheimer’s disease (AD)
During the AD/PD™ (Alzheimer’s and Parkinson’s disease) Conference in March 2026, a consistent theme emerged across scientific and industry discussions.
See article and view paper
Capability Without Coherence
Capability Without Coherence
A perspective on why pharma’s tools are outpacing its ability to deliver value.
See article and view paper
Medical Affairs KPIs
Medical Affairs KPIs
The purpose of this paper is to describe how effective Medical Affairs KPIs can be developed as straightforwardly as possible, and to present key elements that organisations should consider in their own KPI dashboards.
See article and view paper
Medical operations of the future
Medical operations of the future
As Medical Affairs organisations continue to evolve, the 'Medical Operations' or 'Medical Excellence' group is becoming increasingly important. This paper explores how Medical Operations groups can best evolve to...
See article and view paper
DCTs: achieving our ambition
DCTs: achieving our ambition
Decentralised clinical trials (DCTs) present a biopharmaceutical company with a series of opportunities and challenges. We highlight the challenges and examine...